<scp>VI‐RADS</scp> for Bladder Cancer: Current Applications and Future Developments

DOI Web Site Web Site 1 Citations
  • Valeria Panebianco
    Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
  • Martina Pecoraro
    Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
  • Francesco Del Giudice
    Department of Maternal‐Infant and Urological Sciences Sapienza/Policlinico Umberto I Rome Italy
  • Mitsuru Takeuchi
    Department of Radiology Radiolonet Tokai Nagoya Japan
  • Valdair F. Muglia
    Department of Medical Images, Radiation Therapy and Oncohematology, Ribeirao Preto Medical School University of Sao Paulo Ribeirao Preto Brazil
  • Emanuele Messina
    Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
  • Stefano Cipollari
    Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
  • Gianluca Giannarini
    Urology Unit Academic Medical Centre “Santa Maria della Misericordia” Udine Italy
  • Carlo Catalano
    Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
  • Yoshifumi Narumi
    Department of Healthcare Tachibana University Kyoto Japan

Description

<jats:sec><jats:label /><jats:p>Bladder cancer (BCa) is among the ten most frequent cancers globally. It is the tumor with the highest lifetime treatment‐associated costs, and among the tumors with the heaviest impacts on postoperative quality of life. The purpose of this article is to review the current applications and future perspectives of the Vesical Imaging Reporting and Data System (VI‐RADS). VI‐RADS is a newly developed scoring system aimed at standardization of MRI acquisition, interpretation, and reporting for BCa. An insight will be given on the BCa natural history, current MRI applications for local BCa staging with assessment of muscle invasiveness, and clinical implications of the score for disease management. Future applications include risk stratification of nonmuscle invasive BCa, surveillance, and prediction and monitoring of therapy response.</jats:p></jats:sec><jats:sec><jats:title>Level of Evidence</jats:title><jats:p>3</jats:p></jats:sec><jats:sec><jats:title>Technical Efficacy Stage</jats:title><jats:p>2</jats:p></jats:sec>

Journal

Citations (1)*help

See more

Report a problem

Back to top